Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3804138 | 0.87 | TSHR (0.55) | ALDH1A1TSHRCETPLMNAMAPK1 | |
| SCHEMBL3804139 | 0.87 | TSHR (0.59) | ALDH1A1TSHRCETPLMNAMAPK1 | |
| SCHEMBL31480892 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TSHRCETPLMNAMAPK1 | |
| SCHEMBL21446911 | 0.86 | TSHR (0.69) | ALDH1A1TSHRCETPLMNAMAPK1 | |
| SCHEMBL19509036 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TSHRCETPLMNAMAPK1 | |
| SCHEMBL21189480 | 0.84 | TSHR (0.51) | ALDH1A1TSHRCETPLMNAMAPK1 | |
| SCHEMBL31480665 | 0.83 | ALDH1A1 (0.56) | ALDH1A1TSHRCETPLMNAMAPK1 | |
| SCHEMBL31404912 | 0.83 | KMT2A (0.62) | ALDH1A1TSHRLMNAMAPK1SLC6A2 | |
| SCHEMBL5379773 | 0.82 | TSHR (0.61) | ALDH1A1TSHRCETPALPGPTK2B | |
| SCHEMBL13347322 | 0.81 | TSHR (0.49) | ALDH1A1TSHRCETPLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714961-A2 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4209483-B1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4364727-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3762386-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3762386-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-112218867-B | Adenosine receptor antagonists and uses thereof | 泰昂治疗公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4209483-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220251123-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2022-08-11 | — | — | US | disclosed |
| US-20110300132-A1 | 4-AMINOQUINAZOLINE PRODRUGS | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110300132-A1 | 4-AMINOQUINAZOLINE PRODRUGS | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20100221221-A1 | N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010019557-A1 | N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010005585-A2 | 4-AMINOQUINAZOLINE PRODRUGS | CONCERT PHARMACEUTICALS INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-1957464-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | Abbott Laboratories (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007050732-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | ABBOTT LABORATORIES (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| EP-0747385-B1 | Prodrugs of paclitaxel derivatives | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0747385-A1 | Prodrugs of paclitaxel derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | C5AR2, C5AR1, C3AR1 | ALDH1A1 2620/4885TSHR 384/4885CETP 2209/4885 |
| US-20100221221-A1 | N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES | NME2, NME1, ABL1 | ALDH1A1 3768/4885TSHR 3305/4885CETP 4249/4885 |
| US-20220251123-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 1941/4885TSHR 2909/4885CETP 3494/4885 |
| US-20110300132-A1 | 4-AMINOQUINAZOLINE PRODRUGS | ERBB2, ERBB4, ERBB3 | ALDH1A1 2443/4885TSHR 2996/4885CETP 4353/4885 |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | TRPV1, TRPV3, TRPA1 | ALDH1A1 583/4885TSHR 2169/4885CETP 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.